The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
Open accessAbstract
Prostate cancer is the second-leading cause of cancer-related mortality in men in Western societies. Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer cells, and androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally advanced and metastatic disease. Although a majority of patients initially respond to ADT, most will eventually develop castrate resistance, defined as disease progression despite serum testosterone levels of <20 ng/dl. The recent discovery that AR signaling persists during systemic castration via intratumoral production of androgens led to the development of novel anti-androgen therapies including abiraterone acetate and enzalutamide. Although these agents effectively palliate symptoms and prolong life, metastatic castration-resistant prostate cancer remains incurable. An increased understanding of the mechanisms that underlie the pathogenesis of castrate resistance is therefore needed to develop novel therapeutic approaches for this disease. The aim of this review is to summarize the current literature on the biology and treatment of castrate-resistant prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Cadherin Cell Adhesion Receptors as a Morphogenetic Regulator
Takeichi, M. (1991) · Science · doi:10.1126/science.2006419 · Cited by 3,284
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
The insulin-like growth factor system and cancer
LeRoith, D., & Roberts, C. T. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00159-9 · Cited by 1,124
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., Rathkopf, D., Shelkey, J., Yu, E. Y., Alumkal, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., Chambers, C., Fuerth, B. J., Viollet, B., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.001 · Cited by 911
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
Harris, W. P., Mostaghel, E. A., Nelson, P. S., & Montgomery, B. (2009) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1296 · Cited by 877
TGF-β signaling: positive and negative effects on tumorigenesis
Wakefield, L. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00259-3 · Cited by 827
Myc-driven murine prostate cancer shares molecular features with human prostate tumors
Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., Thomas, G. V., & Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00197-1 · Cited by 816
Higano, C. S., Schellhammer, P. F., Small, E. J., Burch, P. A., Nemunaitis, J., Yuh, L., Provost, N., & Frohlich, M. W. (2009) · Cancer · doi:10.1002/cncr.24429 · Cited by 810
Padua, D., & Massagué, J. (2009) · Cell Research · doi:10.1038/cr.2008.316 · Cited by 809
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., & Wilson, E. M. (2001) · PubMed · Cited by 708
Li, Y., Chan, S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A. T., & Dehm, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3630 · Cited by 680
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
The IGF‐1 receptor in cancer biology
Baserga, R., Peruzzi, F., & Reiss, K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11487 · Cited by 642
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Massie, C. E., Lynch, A., Ramos‐Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.158 · Cited by 624
Interplay of Cadherin-Mediated Cell Adhesion and Canonical Wnt Signaling
Heuberger, J., & Birchmeier, W. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002915 · Cited by 619
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 596
Bubendorf, L., Kononen, J., Koivisto, P. A., Schraml, P., Moch, H., Gasser, T. C., Willi, N., Mihatsch, M. J., Sauter, G., & Kallioniemi, O. (1999) · PubMed · Cited by 594
Brognard, J., Sierecki, E., Gao, T., & Newton, A. C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.017 · Cited by 591
Hu, R., Lu, C., Mostaghel, E. A., Yegnasubramanian, S., Gurel, M., Tannahill, C., Edwards, J., Isaacs, W. B., Nelson, P. S., Bluemn, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3892 · Cited by 583
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Zhao, X.-Y., Malloy, P. J., Krishnan, A. V., Swami, S., Navone, N. M., Peehl, D. M., & Feldman, D. (2000) · Nature Medicine · doi:10.1038/76287 · Cited by 536
Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H. M., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3667 · Cited by 533
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
Mulholland, D. J., Tran, L. M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., Garraway, I. P., Huang, J., Graeber, T. G., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.006 · Cited by 516
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
Ding, Z., Wu, C.-J., Chu, G. C., Xiao, Y., Ho, D., Zhang, J., Perry, S. R., Labrot, E. S., Wu, X., Lis, R., et al. (2011) · Nature · doi:10.1038/nature09677 · Cited by 515
Caveolin-1 in oncogenic transformation, cancer, and metastasis
Williams, T. M., & Lisanti, M. P. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00458.2004 · Cited by 511
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family
Xu, J., Wu, R.-C., & O'Malley, B. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2695 · Cited by 488
Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization.
Visakorpi, T., Kallioniemi, A. H., Syvänen, A. C., HYYTINEN, E.-R., Karhu, R., Tammela, T. L. J., Isola, J. J., & Kallioniemi, O. (1995) · PubMed · Cited by 480
Mulholland, D. J., Kobayashi, N., Ruscetti, M., Zhi, A., Tran, L. M., Huang, J., Gleave, M., & Wu, H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3132 · Cited by 478
Cai, C., He, H. H., Chen, S., Coleman, I., Wang, H., Fang, Z., Chen, S., Nelson, P. S., Liu, X. S., Brown, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.001 · Cited by 454
Lin, H.-K. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf406 · Cited by 450
Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., Corn, P. G., Vogelzang, N. J., Small, E. J., Harzstark, A. L., Gordon, M. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0494 · Cited by 446
Self-citationNuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis
Gurel, B., Iwata, T., M Koh, C., Jenkins, R. B., Lan, F., Van Dang, C., Hicks, J. L., Morgan, J., Cornish, T. C., Sutcliffe, S., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.111 · Cited by 441
Culig, Z. (1993) · Molecular Endocrinology · doi:10.1210/me.7.12.1541 · Cited by 440
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
Edwards, J., Krishna, N. S., Grigor, K. M., & Bartlett, J. M. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601127 · Cited by 424
Jeter, C. R., Liu, B., Liu, X., Chen, X., Liu, C., Calhoun-Davis, T., Repass, J., Zaehres, H., Shen, J. J., & Tang, D. G. (2011) · Oncogene · doi:10.1038/onc.2011.114 · Cited by 394
Kinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34764 · Cited by 391
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Muranen, T., Selfors, L. M., Worster, D. T., Iwanicki, M. P., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 384
Alternatively spliced androgen receptor variants
Dehm, S. M., & Tindall, D. J. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0141 · Cited by 380
Interaction of Nuclear Receptors with the Wnt/β-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Mulholland, D. J., Dedhar, S., Coetzee, G. A., & Nelson, C. C. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0034 · Cited by 377
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
Sun, Y., Wang, B.-E., Leong, K. G., Yue, P., Li, L., Jhunjhunwala, S., Chen, D., Seo, K., Modrusan, Z., Gao, W.-Q., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3004 · Cited by 357
Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ
Thompson, T. C., Southgate, J., Kitchener, G., & Land, H. (1989) · Cell · doi:10.1016/0092-8674(89)90625-9 · Cited by 352
Self-citationBeta-catenin affects androgen receptor transcriptional activity and ligand specificity.
Truica, C. I., Byers, S. W., & Gelmann, E. P. (2000) · PubMed · Cited by 350
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Chang, K.-H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y. D., Auchus, R. J., & Sharifi, N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107898108 · Cited by 346
Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344
Sharma, A., Yeow, W.-S., Ertel, A., Coleman, I., Clegg, N., Thangavel, C., Morrissey, C., Zhang, X., Comstock, C. E. S., Witkiewicz, A. K., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44239 · Cited by 331
Elevated expression of caveolin is associated with prostate and breast cancer.
Yang, G., Truong, L. D., Timme, T. L., Ren, C., Wheeler, T. M., Park, S. H., Nasu, Y., Bangma, C. H., Kattan, M. W., Scardino, P. T., et al. (1998) · PubMed · Cited by 331
Self-citationUeda, T., Mawji, N. R., Bruchovsky, N., & Sadar, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203313200 · Cited by 311
Acevedo, V. D., Gangula, R. D., Freeman, K. W., Li, R., Zhang, Y., Wang, F., Ayala, G. E., Peterson, L. E., Ittmann, M., & Spencer, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.004 · Cited by 308
Wikström, P., Stattin, P., Franck-Lissbrant, I., Damber, J.-E., & Bergh, A. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(19980915)37:1<19::aid-pros4>3.0.co;2-3 · Cited by 307
Genetic Alterations in Hormone-Refractory Recurrent Prostate Carcinomas
Nupponen, N. N., Kakkola, L., Koivisto, P., & Visakorpi, T. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65554-x · Cited by 307
Li, L., Ren, C. H., Tahir, S. A., Ren, C., & Thompson, T. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9389-9404.2003 · Cited by 291
Self-citationOvercoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism
Zhao, Y., Liu, H., Liu, Z., Ding, Y., LeDoux, S. P., Wilson, G. L., Voellmy, R., Lin, Y., Lin, W., Nahta, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0127 · Cited by 289
Wnt/β-catenin signalling in prostate cancer
Kypta, R. M., & Waxman, J. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.116 · Cited by 275
A spatial and temporal map of C. elegans gene expression
Spencer, W. C., Zeller, G., Watson, J. D., Henz, S. R., Watkins, K. L., McWhirter, R. D., Petersen, S., Sreedharan, V. T., Widmer, C., Jo, J., et al. (2011) · Genome Research · doi:10.1101/gr.114595.110 · Cited by 269
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Attard, G., Cooper, C. S., & de Bono, J. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.11.006 · Cited by 242
Burfeind, P., Chernicky, C. L., Rininsland, F., Ilan, J., & Ilan, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.7263 · Cited by 238
Nickerson, T., Chang, F., Lorimer, D., Smeekens, S. P., Sawyers, C. L., & Pollak, M. (2001) · PubMed · Cited by 231
Stiles, B., Groszer, M., Wang, S., Jiao, J., & Wu, H. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2004.06.008 · Cited by 230
Zhu, M., & Kyprianou, N. (2010) · The FASEB Journal · doi:10.1096/fj.09-136994 · Cited by 226
Myc confers androgen-independent prostate cancer cell growth
Bernard, D., Pourtier, A., Gil, J., & Beach, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19035 · Cited by 224
Androgen receptor gene expression in human prostate carcinoma cell lines.
Tilley, W. D., Wilson, C. M., Marcelli, M., et al. (1990) · PubMed · Cited by 218
Wilkes, M. C., Mitchell, H., Penheiter, S. G., Doré, J. J., Suzuki, K., Edens, M., Sharma, D. K., Pagano, R. E., & Leof, E. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1522 · Cited by 216
Steinkamp, M. P., O'Mahony, O. A., Brogley, M., Rehman, H., LaPensee, E. W., Dhanasekaran, S., Hofer, M. D., Kuefer, R., Chinnaiyan, A., Rubin, M. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3605 · Cited by 210
Androgens Up-regulate the Insulin-like Growth Factor-I Receptor in Prostate Cancer Cells
Pandini, G., Mineo, R., Frasca, F., Roberts, C. T., Marcelli, M., Vigneri, R., & Belfiore, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1837 · Cited by 208
Hu, R., Isaacs, W. B., & Luo, J. (2011) · The Prostate · doi:10.1002/pros.21382 · Cited by 207
Mechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 204
Verras, M., Lee, J., Xue, H., Li, T.-H., Wang, Y., & Sun, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3552 · Cited by 203
Li, Y., Hwang, T. H., Oseth, L. A., Hauge, A., Vessella, R. L., Schmechel, S. C., Hirsch, B., Beckman, K. B., Silverstein, K. A., & Dehm, S. M. (2012) · Oncogene · doi:10.1038/onc.2011.637 · Cited by 202
Memarzadeh, S., Xin, L., Mulholland, D. J., Mansukhani, A., Wu, H., Teitell, M. A., & Witte, O. N. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.002 · Cited by 201
Ros, S., Santos, C. R., Moco, S., Baenke, F., Kelly, G., Howell, M., Zamboni, N., & Schulze, A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0234 · Cited by 201
Mitsiades, N., Sung, C. C., Schultz, N., Danila, D. C., He, B., Eedunuri, V. K., Fleisher, M., Sander, C., Sawyers, C. L., & Scher, H. I. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1335 · Cited by 197
Viñals, F., & Pouysségur, J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7218-7230.2001 · Cited by 191
Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
Efstathiou, E., Titus, M., Tsavachidou, D., Tzelepi, V., Wen, S., Hoang, A., Molina, A., Chieffo, N., Smith, L. A., Karlou, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7675 · Cited by 189
Li, L., Yang, G., Ebara, S., Satoh, T., Nasu, Y., Timme, T. L., Ren, C., Wang, J., Tahir, S. A., & Thompson, T. C. (2001) · PubMed · Cited by 188
Self-citationNasu, Y., Timme, T. L., Yang, G., Bangma, C. H., Li, L., Ren, C., Park, S. H., DeLeon, M., Wang, J., & Thompson, T. C. (1998) · Nature Medicine · doi:10.1038/2048 · Cited by 181
Self-citationMulholland, D. J., Cheng, H., Reid, K., Rennie, P. S., & Nelson, C. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200135200 · Cited by 172
Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P. A., Sawyers, C. L., & Wu, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4202 · Cited by 172
Small Molecule Inhibitors Targeting the “Achilles' Heel” of Androgen Receptor Activity
Sadar, M. D. (2011) · Cancer Research · doi:10.1158/0008-5472.can_10-3398 · Cited by 169
Agoulnik, I. U., Vaid, A., Nakka, M., Alvarado, M., Bingman, W. E., Erdem, H., Frolov, A., Smith, C. L., Ayala, G. E., Ittmann, M. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1023 · Cited by 168
Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis
Lai, S.-L., Chien, A. J., & Moon, R. T. (2009) · Cell Research · doi:10.1038/cr.2009.41 · Cited by 161
Mao, X., Yu, Y., Boyd, L. K., Ren, G., Lin, D., Chaplin, T., Kudahetti, S. C., Stankiewicz, E., Xue, L., Beltrán, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4074 · Cited by 157
Escaping from the TGF anti-proliferative control
Seoane, J. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl068 · Cited by 153
Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor
Chesire, D. R., & Isaacs, W. B. (2002) · Oncogene · doi:10.1038/sj.onc.1206049 · Cited by 151
Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells.
TAILLE, A. D. L., Rubin, M. A., Chen, M., Vacherot, F., de Medina, S. G. D., Burchardt, M., Buttyan, R., & Chopin, D. K. (2003) · PubMed · Cited by 151
Karan, D., Kelly, D. L., Rizzino, A., Lin, M., & Batra, S. K. (2002) · Carcinogenesis · doi:10.1093/carcin/23.6.967 · Cited by 138
Iwata, T., Schultz, D., Hicks, J. L., Hubbard, G. K., Mutton, L. N., Lotan, T. L., Bethel, C. R., Lotz, M. T., Yegnasubramanian, S., Nelson, W. G., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009427 · Cited by 137
Lin, H., Hu, Y., Lee, D., & Chang, C. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0117 · Cited by 134
Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
Dayyani, F., Gallick, G. E., Logothetis, C. J., & Corn, P. G. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr362 · Cited by 131
Self-citationPROSTATIC CANCER TREATED BY ORCHIECTOMY: THE FIVE YEAR RESULTS
Huggins, C. (1946) · JAMA · doi:10.1001/jama.1946.02870240008003 · Cited by 129
Saloniemi, T., Jokela, H., Strauss, L., Pakarinen, P., & POUTANEN, M. H. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0315 · Cited by 129
Expression of transforming growth factor-beta 1 in prostate cancer
Steiner, M. S., Zhou, Z. Z., Tonb, D. C., & Barrack, E. R. (1994) · Endocrinology · doi:10.1210/endo.135.5.7956947 · Cited by 128
Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
Marques, R. B., Dits, N. F. J., Erkens‐Schulze, S., van Weerden, W. M., & Jenster, G. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013500 · Cited by 127
Moon, J.-S., Jin, W.-J., Kwak, J.-H., Kim, H.-J., Yun, M.-J., KIM, J.-W., Park, S. W., & Kim, K.-S. (2011) · Biochemical Journal · doi:10.1042/bj20101104 · Cited by 125
Caveolin-1: A tumor-promoting role in human cancer
Shatz, M., & Liscovitch, M. (2008) · International Journal of Radiation Biology · doi:10.1080/09553000701745293 · Cited by 125
Wang, Y., Михайлова, М. А., Bose, S., Pan, C.-X., White, R. D., & Ghosh, P. (2008) · Oncogene · doi:10.1038/onc.2008.318 · Cited by 112
Advancing a clinically relevant perspective of the clonal nature of cancer
Ruiz, C. F., Lenkiewicz, E., Evers, L., Holley, T., Robeson, A., Kiefer, J., Demeure, M. J., Hollingsworth, M. A., Shen, M., Prunkard, D. E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104009108 · Cited by 111
Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression
Jones, E., Pu, H., & Kyprianou, N. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802705696 · Cited by 109
Haapala, K., HYYTINEN, E.-R., Roiha, M., Laurila, M., Rantala, I. S., Helin, H. J., & Koivisto, P. A. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780378 · Cited by 106
Mulholland, D. J., Read, J. T., Rennie, P. S., Cox, M., & Nelson, C. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206802 · Cited by 104
The role of caveolin-1 in prostate cancer: clinical implications
Thompson, T. C., Tahir, S. A., Li, L., Watanabe, M., Naruishi, K., Yang, G., Kadmon, D., Logothetis, C. J., Troncoso, P., Ren, C., et al. (2009) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2009.29 · Cited by 96
Self-citationVaz, C. V., Alves, M. G., Marques, R., Moreira, P. I., Oliveira, P. F., Maia, C. J., & Socorro, S. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.08.013 · Cited by 96
Chee, K. G., Longmate, J., Quinn, D. I., Chatta, G. S., Pinski, J., Twardowski, P. W., Pan, C.-X., Cambio, A., Evans, C. P., Gandara, D. R., et al. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.031 · Cited by 92
Portrait of PTEN: Messages from mutant mice
Suzuki, A., Nakano, T., Mak, T. W., & Sasaki, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00670.x · Cited by 92
Caveolin-1–LRP6 Signaling Module Stimulates Aerobic Glycolysis in Prostate Cancer
Tahir, S. A., Yang, G., Goltsov, A. A., Song, K., Ren, C., Wang, J., Chang, W., & Thompson, T. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3040 · Cited by 92
Self-citationGao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., & Abate-Shen, C. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1637 · Cited by 87
Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.
Mahajan, K., Challa, S., Coppola, D., Lawrence, H., Luo, Y., Gevariya, H., Zhu, W., Chen, Y. A., Lawrence, N. J., & Mahajan, N. P. (2010) · The Prostate · doi:10.1002/pros.21163 · Cited by 86
Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.
Tahir, S. A., Ren, C., Timme, T. L., Gdor, Y., Hoogeveen, R. C., Morrisett, J. D., Frolov, A., Ayala, G., Wheeler, T. M., & Thompson, T. C. (2003) · PubMed · Cited by 86
Self-citationDehm, S. M., Regan, K. M., Schmidt, L. J., & Tindall, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1267 · Cited by 84
Bakin, R. E., Gioeli, D. G., Bissonette, E. A., & Weber, M. J. (2003) · PubMed · Cited by 83
Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer
Nakabayashi, M., Werner, L., Courtney, K. D., Buckle, G. C., Oh, W. K., Bubley, G. J., Hayes, J. H., Weckstein, D. J., Elfiky, A. A., Sims, D. M., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11456.x · Cited by 82
Varkaris, A. S., Corn, P. G., Gaur, S., Dayyani, F., Logothetis, C. J., & Gallick, G. E. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.631523 · Cited by 80
Self-citationActivation of β-Catenin Signaling in Androgen Receptor–Negative Prostate Cancer Cells
Wan, X., Liu, J., Lu, J.-F., Tzelepi, V., Yang, J., Starbuck, M. W., Diao, L., Wang, J., Efstathiou, E., Vazquez, E. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2521 · Cited by 79
Tumor Cell–Secreted Caveolin-1 Has Proangiogenic Activities in Prostate Cancer
Tahir, S. A., Yang, G., Goltsov, A. A., Watanabe, M., Tabata, K.-I., Addai, J. B., Fattah, E. M. A., Kadmon, D., & Thompson, T. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2668 · Cited by 79
Self-citationZhang, W., Zhu, J. J., Efferson, C. L., Ware, C., Tammam, J. G., Angagaw, M. H., Laskey, J., Bettano, K. A., Kasibhatla, S., Reilly, J. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4385 · Cited by 78
Dai, B., Chen, H., Guo, S., Yang, X., Linn, D. E., Sun, F., Li, W., Guo, Z., Xu, K., Kim, O., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4610 · Cited by 76
Tahir, S. A., Frolov, A., Hayes, T. G., Mims, M. P., Miles, B. J., Lerner, S. P., Wheeler, T. M., Ayala, G., Thompson, T. C., & Kadmon, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0417 · Cited by 63
Self-citationPromoter methylation correlates with reduced Smad4 expression in advanced prostate cancer
Aitchison, A., Veerakumarasivam, A., Vias, M., Kumar, R., Hamdy, F. C., Neal, D. E., & Mills, I. G. (2008) · The Prostate · doi:10.1002/pros.20730 · Cited by 62
Androgen receptor levels are upregulated by Akt in prostate cancer
Ha, S., Ruoff, R., Kahoud, N., Franke, T. F., & Logan, S. K. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0204 · Cited by 60
Caveolin, cholesterol and Ras signalling
Sternberg, P. W., & Schmid, S. L. (1999) · Nature Cell Biology · doi:10.1038/10028 · Cited by 57
Transcriptional regulation of theTGF-β1promoter by androgen receptor
Wei, Q., Gao, S., & Wang, Z. (2008) · Biochemical Journal · doi:10.1042/bj20080651 · Cited by 55
Themsche, C. V., Mathieu, I., Parent, S., & Asselin, É. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608497200 · Cited by 54
Heidegger, I. M., Ofer, P., Doppler, W., Rotter, V., Klocker, H., & Massoner, P. (2012) · Endocrinology · doi:10.1210/en.2012-1348 · Cited by 50
Sirotnak, F. M., She, Y., Khokhar, N. Z., Hayes, P., Gerald, W. L., & Scher, H. I. (2004) · Molecular Carcinogenesis · doi:10.1002/mc.20051 · Cited by 47
Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate
Nakano, A., Miki, H., Nakamura, S., Harada, T., Oda, A., Amou, H., Fujii, S., Kagawa, K., Takeuchi, K., Ozaki, S., et al. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9412-9 · Cited by 46
Yang, G., Goltsov, A. A., Ren, C., Kurosaka, S., Edamura, K., Logothetis, R., DeMayo, F. J., Troncoso, P., Blando, J. M., DiGiovanni, J., et al. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0451 · Cited by 46
Self-citationAndrogen Receptor Mutations in High-Grade Prostate Cancer before Hormonal Therapy
Thompson, J. S., Hyytinen, E., Haapala, K., Rantala, I. S., Helin, H. J., Jänne, O. A., Palvimo, J. J., & Koivisto, P. A. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000107262.40402.44 · Cited by 45
Li, L., Ren, C., Yang, G., Goltsov, A. A., Tabata, K.-I., & Thompson, T. C. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0255 · Cited by 44
Self-citationThe insulin-like growth factor system as a treatment target in breast cancer
Yee, D. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70131-0 · Cited by 39
FGF signalling in prostate development, tissue homoeostasis and tumorigenesis
Lin, Y., & Wang, F. (2010) · Bioscience Reports · doi:10.1042/bsr20100020 · Cited by 31
The insulin-like growth factor system as a treatment target in breast cancer
Yee, D. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.34060 · Cited by 30
Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models
Tahir, S. A., Kurosaka, S., Tanimoto, R., Goltsov, A. A., Park, S., & Thompson, T. C. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.22633 · Cited by 24
Self-citationWei, Q., Gao, S., Chu, J., Zhou, L., & Wang, Z. (2011) · Journal of Andrology · doi:10.2164/jandrol.110.011999 · Cited by 20
Cited by
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.039 · Cited by 733
“This finding suggests that DNA copy gain affecting this locus, commonly by tandem duplication, may be a frequent mechanism by which prostate tumor cells initially develop ADT resistance (Karantanos et al., 2013).”
Il-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0266-0 · Cited by 394
Han, X., Wang, C., Qin, C., Xiang, W., Fernandez-Salas, E., Yang, C.-Y., Wang, M., Zhao, L., Xu, T., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01631 · Cited by 381
WNT signalling in prostate cancer
Murillo-Garzón, V., & Kypta, R. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.144 · Cited by 361
Metadata
- Authors
- Karantanos, T., Corn, P. G., & Thompson, T. C.
- Venue
- Oncogene
- Published
- 2013-06-10
- Volume
- 32
- Issue
- 49
- Pages
- 5501-5511
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2159810380
- Cited by
- 866
- References
- 156
- FWCI
- 47.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.